

## ZELTIA NEWS:

# PHARMAMAR FRANCE COMMENCES COMMERCIAL ACTIVITY

**Madrid, 26 May 2014:** PharmaMar S.A., Pharma Mar S.A.'s French subsidiary, based in Paris, has commenced the commercial activity and will have a sales team of fourteen.

PharmaMar is committed to an international presence and is strengthening its position in view of potential licensing-in agreements.

France is Europe's second-largest oncology market, and its notable growth potential together with PharmaMar's solid sales network are expected to drive sales in that country.

### **About PharmaMar**

PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondelis® is the first marine-based antitumour drug. PharmaMar has four other compounds in clinical development: Aplidin®, Zalypsis®, PM1183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

### **About Zeltia**

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading company in molecular diagnostics based on DNA analysis; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).

### **Important note**

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Zeltia, S.A. (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or

subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

**For more information +34 91 444 4500**

This note is also available on the PharmaMar web site: [www.pharmamar.com](http://www.pharmamar.com) and at Zeltia's website: [www.zeltia.com](http://www.zeltia.com)